NOVO NORDISK A/S

Their core work

Novo Nordisk is a global pharmaceutical company headquartered in Denmark, historically focused on diabetes care, that participates extensively in large-scale European public-private research initiatives. Within H2020, they contribute clinical data, patient cohorts, and drug development expertise to consortia tackling diabetes, rare diseases, neurodegeneration, and clinical trial innovation. Their participation spans biomarker discovery, iPSC stem cell banking, decentralized clinical trials, and AI-driven pathology — reflecting the breadth of a major pharma company investing in pre-competitive research across its therapeutic pipeline.

What they specialise in

How they've shifted over time

In the early H2020 period (2015–2018), Novo Nordisk's participation centered firmly on diabetes — type 1 prevention (INNODIA), type 2 biomarkers (RHAPSODY), diabetic kidney disease (BEAt-DKD) — alongside regulatory pathway innovation (ADAPT-SMART). From 2019 onward, their portfolio diversified significantly into rare diseases (SCREEN4CARE, ARDAT), neuroscience (EBiSC2, IM2PACT, NSC-Reconstruct), and clinical trial modernization (Trials@Home, EU-PEARL). This broadening mirrors Novo Nordisk's corporate expansion beyond its traditional diabetes stronghold into obesity, rare blood disorders, and neurological conditions.

Novo Nordisk is moving from a diabetes-focused participant toward a broad therapeutic platform investor, with growing emphasis on AI-driven diagnostics, decentralized clinical trials, and rare disease gene therapies.

How they like to work

Novo Nordisk never coordinates H2020 projects — all 28 participations are as a partner or third party. This is characteristic of large pharmaceutical companies in IMI (Innovative Medicines Initiative) public-private partnerships, where industry contributes in-kind resources (data, compounds, clinical expertise) rather than leading the administrative coordination. With 457 unique consortium partners across 34 countries, they operate as a high-connectivity hub, joining large consortia (typically 20–40 partners) rather than small focused teams.

Novo Nordisk has collaborated with 457 unique partners across 34 countries, making them one of the most broadly connected pharma participants in H2020 health research. Their network spans major academic medical centres, biotech SMEs, regulatory bodies, and patient organizations across virtually all EU member states.

What sets them apart

As one of the world's largest insulin and diabetes care manufacturers, Novo Nordisk brings unmatched clinical datasets, patient access, and regulatory experience to any consortium working on metabolic diseases or adjacent therapeutic areas. Unlike academic partners, they offer direct pharmaceutical development pipeline insight — meaning research outputs have a realistic path to market adoption. Their recent diversification into rare diseases, neuroscience, and digital health means they can now contribute across a much wider range of health consortia than their traditional diabetes reputation suggests.

Highlights from their portfolio

• INNODIA / INNODIA HARVEST
  A two-phase type 1 diabetes initiative spanning 2015–2024 that built a pan-European biobank and clinical trial network — directly aligned with Novo Nordisk's core business.
• EU-PEARL
  Pioneered patient-centric platform trial designs using Bayesian statistics across four disease areas including major depressive disorder and tuberculosis — a departure from Novo Nordisk's metabolic focus.
• SCREEN4CARE
  Combines newborn genetic screening with machine-learning diagnostic tools for rare neuromuscular diseases, representing Novo Nordisk's push into rare disease and AI diagnostics.